<p>Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic condition that affects around 8–13% of women worldwide. PCOS is defined by hyperandrogenism, insulin resistance, and many reproductive irregularities, providing significant challenges with diagnosis and treatment. Here thoroughly analyzes the many animal models used to conduct PCOS research, focusing on their mechanisms, benefits, and drawbacks. Multiple models, including those influenced by androgens (testosterone and DHEA), estrogen, aromatase inhibitors (such as letrozole), and progesterone receptor antagonists (like RU486), are examined for their capacity to recreate the clinical characteristics of PCOS. Although animal models are frequently employed for their cost-efficiency and simple handling, they provide difficulties in correctly replicating human physiology due to variations in reproductive biology. The research highlights the importance of advanced animal models that represent the complete range of PCOS symptoms seen in humans. Furthermore, it emphasizes the significance of these models in understanding the pathophysiology of PCOS and in developing beneficial therapeutic approaches. Future research must concentrate on improving current models and investigating novel approaches for a more accurate depiction of this complex disease to optimize translational results in clinical conditions.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

An Insight into Experimental Animal Models for Polycystic Ovarian Syndrome and Associated Disorders

  • Surabhi B. Patil,
  • Yogesh A. Kulkarni

摘要

Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic condition that affects around 8–13% of women worldwide. PCOS is defined by hyperandrogenism, insulin resistance, and many reproductive irregularities, providing significant challenges with diagnosis and treatment. Here thoroughly analyzes the many animal models used to conduct PCOS research, focusing on their mechanisms, benefits, and drawbacks. Multiple models, including those influenced by androgens (testosterone and DHEA), estrogen, aromatase inhibitors (such as letrozole), and progesterone receptor antagonists (like RU486), are examined for their capacity to recreate the clinical characteristics of PCOS. Although animal models are frequently employed for their cost-efficiency and simple handling, they provide difficulties in correctly replicating human physiology due to variations in reproductive biology. The research highlights the importance of advanced animal models that represent the complete range of PCOS symptoms seen in humans. Furthermore, it emphasizes the significance of these models in understanding the pathophysiology of PCOS and in developing beneficial therapeutic approaches. Future research must concentrate on improving current models and investigating novel approaches for a more accurate depiction of this complex disease to optimize translational results in clinical conditions.